Synthesis of calix[4]azacrown substituted sulphonamides with antioxidant, acetylcholinesterase, butyrylcholinesterase, tyrosinase and carbonic anhydrase inhibitory action

References

• (a) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
  (b) Capasso C, Supuran CT. An overview of the alpha-beta- and gamma-carbonic anhydrases from bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem 2015;30:325–32.
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Carbon-versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors? J Enzyme Inhib Med Chem 2018;33:485–95.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT, Capasso C. The eta-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin Ther Targets 2015;19:551–63.
   PubMed Web of Science ®Google Scholar
  (b) Del Prete S, De Luca V, De Simone G, et al. Cloning, expression and purification of the complete domain of the g-carbonic anhydrase from Plasmodium falciparum. J Enzyme Inhib Med Chem 2016;31:54–9.
   PubMed Web of Science ®Google Scholar
  (c) Vullo D, Del Prete S, Fisher GM, et al. Sulfonamide inhibition studies of theg-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum. Bioorg Med Chem 2015;23:526–31.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
  (d) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.
   PubMed Web of Science ®Google Scholar
  (e) Supuran CT, Vullo D, Manole G, et al. Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2004;2:49–68.
   PubMedGoogle Scholar
• (a) Akocak S, Ilies MA. Next-generation primary sulfonamide carbonic anhydrase inhibitors. In: Supuran CT, Cappasso C, eds. Targeting carbonic anhydrases. London: Future Science; 2014:35–51.
   Google Scholar
  (b) Akocak S, Alam MR, Shabana AM, et al. PEGylated bis-sulfonamide carbonic anhydrase inhibitors can efficiently control the growth of several carbonic anhydrase IX-expressing carcinomas. J Med Chem 2016;59:5077–88.
   PubMed Web of Science ®Google Scholar
  (c) Shabana AM, Mondal UK, Alam R, et al. pH-Senstive multiligand gold nanoplatform targeting carbonic anhydrase IX enhances the delivery of Doxorubicin to hypoxic tumor spheroids and overcomes the hypoxia-induced chemoresistance. ACS Appl Mater Interfaces 2018;10:17792–808.
   PubMed Web of Science ®Google Scholar
  (d) Akocak S, Supuran CT. Activation of α-, β-, γ-, δ-, ζ-, and η- class of carbonic anhydrases with amines and amino acids: a review. J Enzyme Inhib Med Chem 2019;34:1652–9.
   Google Scholar
• (a) Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020.
   Web of Science ®Google Scholar
  (b) Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin Drug Discov 2019; 14:1175–97.
   PubMed Web of Science ®Google Scholar
  (c) Berrino E, Supuran CT. Novel approaches for designing drugs that interfere with pH regulation. Expert Opin Drug Discov 2019;14:231–48.
   PubMed Web of Science ®Google Scholar
• (a) Gul HI, Yamali C, Yesilyurt F, et al. Microwave-assisted synthesis and bioevaluation of new sulfonamides. J Enzyme Inhib Med Chem 2017;32:369–74.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Carbonic anhydrases and metabolism. Metabolites 2018;8:25.
   PubMed Web of Science ®Google Scholar
  (c) Guzel-Akdemir O, Akdemir A, Karali N, et al. Discovery of novel isatin-based sulfonamides with potent and selective inhibition of the tumor-associated carbonic anhydrase isoforms IX and XII. Org Biomol Chem 2015;13:6493–9.
   PubMed Web of Science ®Google Scholar
  (d) Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012; 112:4421–68.
   PubMed Web of Science ®Google Scholar
  (e) da Silva Cardoso V, Vermelho AB, Ricci Junior E, et al. Antileishmanial activity of sulphonamide nanoemulsions targeting the β-carbonic anhydrase from Leishmania species. J Enzyme Inhib Med Chem 2018;33:850–7.
   PubMed Web of Science ®Google Scholar
  (f) Supuran CT, Capasso C. An overview of the bacterial carbonic anhydrases. Metabolites 2017;7:56.
   PubMed Web of Science ®Google Scholar
• (a) Bag S, Tulsan R, Sood A, et al. Sulfonamides as multifunctional agents for Alzheimer’s disease. Bioorg Med Chem 2015;25:626–30.
   Web of Science ®Google Scholar
  (b) Gocer H, Akincioglu A, Goksu S, et al. Carbonic anhydrase and acetylcholinesterase inhibitory effects of carbamates and sulfamoylcarbamates. J Enzyme Inhib Med Chem 2014;30:316–20.
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Carbonic anhydrase activators. Future Med Chem 2018;10:561–73.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709–12.
   PubMed Web of Science ®Google Scholar
  (b) Gulcin I, Scozzafava A, Supuran CT, et al. The effect of caffeic acid phenethyl ester (CAPE) on metabolic enzymes including acetylcholinesterase, butyrylcholinesterase, glutathione S-transferase, lactoperoxidase, and carbonic anhydrase isoenzymes I, II, IX, and XII. J Enzyme Inhib Med Chem 2016;31:1095–101.
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat 2018;28:713–21.
   PubMed Web of Science ®Google Scholar
• (a) Rishton GM, Retz DM, Tempest PA, et al. Fencyhylamine sulfonamide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer’s disease. J Med Chem 2000;43:2297–9.
   PubMed Web of Science ®Google Scholar
  (b) Gocer H, Topal F, Topal M, et al. Acetylcholinesterase and carbonic anhydrase isoenzymes I and II inhibition profiles of taxifolin. J Enzyme Inhib Med Chem 2016;31:441–7.
   PubMed Web of Science ®Google Scholar
  (c) Provensi G, Carta F, Nocentini A, et al. A new kid on the block? Carbonic anhydrases as possible new targets in Alzheimer’s disease. Int J Mol Sci 2019;20:4724.
   PubMed Web of Science ®Google Scholar
• (a) Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease-insights from amyloid-b metabolism beyond the brain. Nat Rev Neurol 2017;13:612–23.
   PubMed Web of Science ®Google Scholar
  (b) Lolak N, Boga M, Tuneg M, et al. Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile. J Enzyme Inhib Med Chem 2020;35:424–31.
   PubMed Web of Science ®Google Scholar
• (a)Yılmaz S, Akbaba Y, Özgeriş B, et al. Synthesis and inhibitory properties of some carbamates on carbonic anhydrase and acetylcholine esterase. J Enzyme Inhib Med Chem 2016;31:1484–91.
   PubMed Web of Science ®Google Scholar
  (b) Ozgun DO, Yamali C, Gul HI, et al. Inhibitory effects of isatin Mannich bases on carbonic anhydrases, acetylcholinesterase, and butyrylcholinesterase. J Enzyme Inhib Med Chem 2016;31:1498–501.
   PubMed Web of Science ®Google Scholar
  (c) Tars K, Vullo D, Kazaks A, et al. Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. J Med Chem 2013;56:293–300.
   PubMed Web of Science ®Google Scholar
  (d) Nocentini A, Supuran CT, Winum JY. Benzoxaborole compounds for therapeutic uses: a patent review (2010–2018). Expert Opin Ther Pat 2018;28:493–504.
   PubMed Web of Science ®Google Scholar
• (a) Ozgeris B, Goksu S, Kose LP, et al. Acetylcholinesterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds. Bioorg Med Chem 2016;24:2318–29.
   PubMed Web of Science ®Google Scholar
  (b) Akıncıoğlu A, Akıncıoğlu H, Gülçin İ, et al. Discovery of potent carbonic anhydrase and acetylcholine esterase inhibitors: novel sulfamoyl carbamates and sulfamides derived from acetophenones. Bioorg Med Chem 2015;23:3592–602.
   PubMed Web of Science ®Google Scholar
• (a) Yilmaz M, Sayin S. Calixarenes in organo and biomimetic catalysis. In: Neri P, Sessler J, Wang MX, eds. Calixarenes and beyond. Cham: Springer; 2016:719–42.
   Google Scholar
  (b) Bhatti AA, Oguz M, Yilmaz M. New water soluble p-sulphonatocalix [4] arene chemosensor appended with rhodamine for selective detection of Hg2+ ion. J. Mol 2020;1203:127436.
   Google Scholar
• (a) Yilmaz M, Karanastasis AA, Chatziathanasiadou M, et al. Inclusion of quercetin in gold nanoparticles decorated with supramolecular hosts amplifies its tumor targeting properties. ACS Appl. Bio Mater 2019;2:2715–25.
   PubMedGoogle Scholar
  (b) Oguz M, Bhatti AA, Dogan B, et al. Formation of the inclusion complex of water soluble fluorescent calix [4] arene and naringenin: solubility, cytotoxic effect and molecular modeling studies. J Biomol Struct Dyn 2019.
   PubMed Web of Science ®Google Scholar
• (a) Oguz M, Gul A, Karakurt S, Yilmaz M. Synthesis and evaluation of the antitumor activity of Calix [4] arene L-proline derivatives. Bioorg Chem 2020;94:103207.
   PubMed Web of Science ®Google Scholar
  (b) Karakurt S, Kellici TF, Mavromoustakos T, et al. Calixarenes in lipase biocatalysis and cancer therapy. Curr Org Chem 2016;20:1043–57.
   Web of Science ®Google Scholar
  (c) Bardi B, Tosi I, Faroldi F, et al. A calixarene-based fluorescent ratiometric temperature probe. Chem Commun (Camb) 2019;55:8098–101.
   PubMed Web of Science ®Google Scholar
• (a) Gasparello J, Manicardi A, Casnati A, et al. Efficient cell penetration and delivery of peptide nucleic acids by an argininocalix[4]arene. Sci Rep 2019;9:3036.
   PubMed Web of Science ®Google Scholar
  (b) Bayrakci M, Kursunlu AN, Güler E, Ertul Ş. A new calix [4] azacrown ether based boradiazaindacene (Bodipy): selective fluorescence changes towards trivalent lanthanide ions. Dyes Pigm 2013;99:269–74.
   Web of Science ®Google Scholar
  (c) Sestito SE, Facchini FA, Morbioli I, et al. Amphiphilic guanidinocalixarenes inhibit lipopolysaccharide (LPS)- and lectin-stimulated toll-like receptor 4 (TLR4) signaling. J Med Chem 2017;60:4882–92.
   PubMed Web of Science ®Google Scholar
• (a) Rouge P, Pires VS, Gaboriau F, et al. Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes. J Enzyme Inhib Med Chem 2010;25:216–27.
   PubMed Web of Science ®Google Scholar
  (b) Pires VS, Gaboriau F, Guillon J, et al. Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes. J Enzyme Inhib Med Chem 2006;21:261–70.
   PubMed Web of Science ®Google Scholar
  (c) Giuliani M, Morbioli I, Sansone F, Casnati A. Moulding calixarenes for biomacromolecule targeting. Chem Commun (Camb) 2015;51:14140–59.
   PubMed Web of Science ®Google Scholar
• (a) Akocak S, Lolak N, Nocentini A, et al. Synthesis and biological evaluation of novel aromatic and heterocyclic bis-sulfonamide Schiff bases as carbonic anhydrase I, II, VII and IX inhibitors. Bioorg Med Chem 2017;25:3093–7.
   PubMed Web of Science ®Google Scholar
  (b) Akocak S, Lolak N, Bua S, et al. Synthesis and biological evaluation of novel N,N′-diaryl cyanoguanidines acting as potent and selective carbonic anhydrase II inhibitors. Bioorg Chem 2018;77:245–51.
   PubMed Web of Science ®Google Scholar
  (c) De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012;111:117–29.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT, Altamimi ASA, Carta F. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019. Expert Opin Ther Pat 2019;29:781–92.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. The management of glaucoma and macular degeneration. Expert Opin Ther Pat 2019;29:745–7.
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev 2018;38:1799–836.
   PubMed Web of Science ®Google Scholar
  (d) Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2018;27:963–70.
   PubMed Web of Science ®Google Scholar
• (a) Lolak N, Akocak S, Bua S, Supuran CT. Design, synthesis and biological evaluation of ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors. Bioorg Chem 2019;82:117–22.
   PubMed Web of Science ®Google Scholar
  (b) Lolak N, Akocak S, Bua S, et al. Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors. Bioorg Med Chem 2019;27:1588–94.
   PubMed Web of Science ®Google Scholar
  (c) Lolak N, Akocak S, Bua S, et al. Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors. Bioorg Chem 2018;77:542–7.
   PubMed Web of Science ®Google Scholar
  (d) Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018). Expert Opin Ther Pat 2018;28:729–40.
   PubMed Web of Science ®Google Scholar
• Durgun M, Türkeş C, Işık M, et al. Synthesis, characterization, biological evaluation, and in silico studies of novel series sulfonamide derivatives. J Enzyme Inhib Med Chem 2020;35:950–62.
   PubMed Web of Science ®Google Scholar
• Wang L, Li L, Zhou ZH, et al. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction. Eur J Med Chem 2017;136:63.
   PubMed Web of Science ®Google Scholar
• Patel NB, Agravat SN. Synthesis and microbial studies of new pyridine derivatives III. Chin J Chem 2007;25:1363–69.
   Google Scholar
• Sunduru N, Salin O, Gylfe Å, Elofsson M. Design, synthesis and evaluation of novel polypharmacological antichlamydial agents. Eur J Med Chem 2015;101:595–603.
   PubMed Web of Science ®Google Scholar
• Shinde PS, Patil NT. Copper-catalyzed sulfonyl radical-enabled regioselective cyclization of 1, 6-enynes. Eur J Org Chem 2017;2017:3512–15.
   Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
   PubMed Web of Science ®Google Scholar
• (a) Draghici B, Vullo D, Akocak S, et al. Ethylene bis-imidazoles are highly potent and selective activators for isozymes VA and VII of carbonic anhydrase, with a potential nootropic effect. Chem Commun 2014;50:5980–3.
   PubMed Web of Science ®Google Scholar
  (b) Akocak S, Lolak N, Vullo D, et al. Synthesis and biological evaluation of histamine Schiff bases as carbonic anhydrase I, II, IV, VII, and IX activators. J Enzym Inhib Med Ch 2017;32:1305–12.
   PubMed Web of Science ®Google Scholar
  (c) Buzás GM, Supuran CT. The history and rationale of using carbonic anhydrase inhibitors in the treatment of peptic ulcers. In Memoriam Ioan Puşcaş (1932-2015). J Enzyme Inhib Med Chem 2016;31:527–533.
   PubMed Web of Science ®Google Scholar
  d) Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol 2011;2:34.(e) Nishimori I, Onishi S, Takeuchi H, Supuran CT. The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des 2008;14:622–630.
   PubMed Web of Science ®Google Scholar
• (a) Şentürk M, Gülçin İ, Beydemir Ş, et al. In vitro inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds. Chem Biol Drug Des 2011;77:494–499.
   PubMed Web of Science ®Google Scholar
  (b) Temperini C, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. J Med Chem 2006;49:3019–3027.
   PubMed Web of Science ®Google Scholar
  (c) Nocentini A, Bonardi A, Gratteri P, et al. Steroids interfere with human carbonic anhydrase activity by using alternative binding mechanisms. J Enzyme Inhib Med Chem 2018;33:1453–59.
   PubMed Web of Science ®Google Scholar
• (a) Rotondi G, Guglielmi P, Carradori S, et al. Design, synthesis and biological activity of selective hCAs inhibitors based on 2-(benzylsulfinyl)benzoic acid scaffold. J Enzyme Inhib Med Chem 2019;34:1400–13.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:E48.
   PubMed Web of Science ®Google Scholar
  (c) Métayer B, Angeli A, Mingot A, et al. Fluoroenesulphonamides: N-sulphonylurea isosteres showing nanomolar selective cancer-related transmembrane human carbonic anhydrase inhibition. J Enzyme Inhib Med Chem 2018;33:804–808.
   PubMed Web of Science ®Google Scholar
  (d) Casey JR, Morgan PE, Vullo D, et al. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem 2004;47:2337–47.
   PubMed Web of Science ®Google Scholar
• (a) Krall N, Pretto F, Decurtins W, et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl 2014;53:4231–35.
   PubMed Web of Science ®Google Scholar
  (b) Rehman SU, Chohan ZH, Gulnaz F, Supuran CT. In-vitro antibacterial, antifungal and cytotoxic activities of some coumarins and their metal complexes. J Enzyme Inhib Med Chem 2005;20:333–40.
   PubMed Web of Science ®Google Scholar
  (c) Clare BW, Supuran CT. Carbonic anhydrase activators. 3: structure-activity correlations for a series of isozyme II activators. J Pharm Sci 1994;83:768–73.
   PubMed Web of Science ®Google Scholar
  (d) Ammazzalorso A, Carradori S, Angeli A, et al. Fibrate-based N-acylsulphonamides targeting carbonic anhydrases: synthesis, biochemical evaluation, and docking studies. J Enzyme Inhib Med Chem 2019;34:1051–61.
   PubMed Web of Science ®Google Scholar
  (e) Chohan ZH, Munawar A, Supuran CT. Transition metal ion complexes of Schiff-bases. Synthesis, characterization and antibacterial properties. Met Based Drugs 2001;8:137–43.
   PubMedGoogle Scholar
  (f) Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal β-class (Cab) and γ-class (Cam) carbonic anhydrases. Curr Top Med Chem 2007;7:901–908.
   PubMed Web of Science ®Google Scholar
• (a) Köhler K, Hillebrecht A, Schulze Wischeler J, et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl 2007;46:7697–99.
   PubMed Web of Science ®Google Scholar
  (b) Ozensoy Guler O, Capasso C, Supuran CT. A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. J Enzyme Inhib Med Chem 2016;31:689–94.
   PubMed Web of Science ®Google Scholar
  (c) De Simone G, Langella E, Esposito D, et al. Insights into the binding mode of sulphamates and sulphamides to hCA II: crystallographic studies and binding free energy calculations. J Enzyme Inhib Med Chem 2017;32:1002–11.
   PubMed Web of Science ®Google Scholar
  (d) Alper Türkoğlu E, Şentürk M, Supuran CT, Ekinci D. Carbonic anhydrase inhibitory properties of some uracil derivatives. J Enzyme Inhib Med Chem 2017;32:74–7.
   PubMed Web of Science ®Google Scholar
  (e) Alterio V, Esposito D, Monti SM, et al. Crystal structure of the human carbonic anhydrase II adduct with 1-(4-sulfamoylphenyl-ethyl)-2,4,6-triphenylpyridinium perchlorate, a membrane-impermeant, isoform selective inhibitor. J Enzyme Inhib Med Chem 2018;33:151–57.
   PubMed Web of Science ®Google Scholar
• (a) Akocak S, Lolak N, Bua S, et al. a-Carbonic anhydrases are strongly activated by spinaceamine derivatives. Bioorg Med Chem 2019;27:800–4.
   PubMed Web of Science ®Google Scholar
  (b) Akocak S, Lolak N, Bua S, et al. Activation of human a-carbonic anhydrase isoforms I, II, IV and VII with bis-histamine Schiff bases and bis-spinaceamine substituted derivatives. J Enzyme Inhib Med Chem 2019;34:1193–8.
   PubMed Web of Science ®Google Scholar
• Blois MS. Antioxidant determinations by the use of a stable free radical. Nature 1958;181:1199–1200.
   Web of Science ®Google Scholar
• Akocak S, Boga M, Lolak N, et al. Design, synthesis and biological evaluation of 1,3-diaryltriazene-substituted sulfonamides as antioxidant, acetylcholinesterase, and butyrylcholinesterase inhibitors. J Turk Chem Soc Sect A: Chem 2019;6:63–70.
   Google Scholar
• Pellegrini RRN, Proteggente A, Pannala A, et al. Antioxidant activity applying and improved ABTS radical cation decolorization assay. Free Rad Bio Med 1999;26:1231–37.
   PubMed Web of Science ®Google Scholar
• Akocak S, Lolak N, Tuneg M, Boga M. Antioxidant, acetylcholinesterase and butyrylcholinesterase inhibition profiles of histamine Schiff bases. J Turk Chem Soc Sect A: Chem 2019;6:157–64.
   Google Scholar
• Dinis TCP, Madeira VMC, Almeida LM. Action of phenolic derivatives (acetoaminophen, salycilate and 5-aminosalycilate) as inhibitors of membrane lipid preoxidation and as preoxyl radical scavengers. Arc Biochem Biophy 1994;315:161–9.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Hearing VJ, Jiménez M. Mammalian tyrosinase – the critical regulatory control point in melanocyte pigmentation. Int J Biochem 1987;19:1141–47.
   PubMedGoogle Scholar